INTRAVITREAL BEVACIZUMAB FOLLOWED BY FOCAL LASER FOR DIFFUSE DIABETIC MACULAR EDEMA OF RECENT PROGRESSION. A CLINICAL CASE BEVACIZUMAB INTRAVÍTREO SEGUIDO DE LÁSER FOCAL EN EL EDEMA MACULAR DIABÉTICO DIFUSO DE PROGRESIÓN RECIENTE. CASO CLÍNICO

Case report: We report the case of a 48-year-old man with diffuse diabetic macular edema of recent progression treated with two consecutive intravitreal injections of bevacizumab followed by focal laser therapy, with good anatomic and functional response. Discussion: Diffuse diabetic macular edema is difficult to manage and frequently requires multiple therapies. We propose the use of bevacizumab as a strategy to reduce diffuse macular edema, facilitating the application of laser therapy (Arch Soc Esp Oftalmol 2009; 84: 209-212).